0 references
Performance Evaluation of a New HRD Assay (HRDsig) in Ovarian Carcinomas in Australia
Journal of Clinical Laboratory Analysis2025Vol. 39(17), pp. e70085–e70085
Pranav Dorwal, Liyan Song, Priscillia Siswara, Amit Kumar, Julie Robin, Noel Djitro, Anna Fong Na Goh, Ravikiran Vedururu, Bin Yuan, Ashleigh Levine, Suzanne Svobodová, Beena Kumar
Abstract
These findings provide real-world evidence of the performance of a new HRD assay (HRDsig) in ovarian carcinomas.
Related Papers
- → Radioimmunoscintigraphy of Ovarian Tumours with Tc-99m Labelled Monoclonal Antibody-170(1995)1 cited
- [Betaglucuronidase activity in ovarian carcinoma (author's transl)].(1979)
- → On the Validity of Simultaneous Determinations of CA 125, SRA, and CA 72-4 in Patients Suffering from Ovarian Tumors(1993)1 cited
- → Abstract 626: Mechanistic differentiation of targeted DDR agent combinations(2020)
- 34.Experimental Chemotherapy of Human Ovarian Carcinomas (Mesonephroid Carcinoma, Embryonal Carcinoma) Xenotransplanted in Nude Mice : VI Ovarian Tumor and Trophoblastic Tumor(II)(1983)